BONESUPPORT HOLDING AB (publ) publishes 2019 Annual Report and comments on effects of COVID-19
Lund, Sweden, 15:00 CET, 3 April 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, publishes its annual report for 2019 and announces that the outbreak of COVID-19 will have a financial impact on the company during the first half of 2020.
The ongoing COVID-19 epidemic has led to temporary adjustments and reprioritizations in the health care sector, especially in the countries that are the hardest hit by the virus.
When hospitals redistribute resources to intensive care units, elective surgeries get lower priority and get postponed. Non elective procedures such as acute orthopaedic surgery for trauma or severe bone infections are less impacted, but nevertheless BONESUPPORT predicts sales, in the first half of 2020, will be impacted by the COVID-19 outbreak. The impact on full year sales 2020 is unpredictable.
BONESUPPORT is closely following the development of COVID-19 and its impact. The company predicts that the number of electic orthopedic surgeries will return to normal as the pandemic wears off, as COVID-19 has no impact on the underlying need.
The company has taken proactive measures to minimize the risk to the company’s employees and to ensure business continuity.
BONESUPPORT’s 2019 annual report is now available as a PDF on the Group’s website, www.bonesupport.com. A PDF version is also attached to this press release.
This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 15:00 CET on 3 April 2020.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits that its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 155 million in 2019. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.